{
    "accuracy": 64.70588235294117,
    "details": {
        "0": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:The treatment focuses on changing thoughts in order to adjust psychological and personality problems. The treatment is based on the principle that maladaptive behavior (ineffective, self-defeating behavior) is triggered by inappropriate or irrational thinking patterns, called automatic thoughts. Instead of reacting to the reality of a situation, an individual automatically reacts to his or her own distorted viewpoint of the situation. Cognitive therapy is a treatment option for a number of mental disorders, including agoraphobia, Alzheimer's disease, anxiety or panic disorder, attention deficit-hyperactivity disorder (ADHD), eating disorders, mood disorders, obsessive-compulsive disorder (OCD), personality disorders, post-traumatic stress disorder (PTSD), psychotic disorders, schizophrenia, social phobia, and substance abuse disorders. Cognitive therapy is usually administered in an out-patient setting (clinic or doctor's office) by a therapist trained or certified in cognitive therapy techniques. Therapists are psychologists (Ph.D., Psy.D., Ed.D., or M.A. degree), or psychiatrists (M.D. trained in psychiatry). Validity testing. The therapist asks the patient to defend his or her thoughts and beliefs. If the patient cannot produce objective evidence supporting his or her assumptions, the invalidity, or faulty nature, is exposed. The patient is asked to imagine a difficult situation he or she has encountered in the past, and then works with the therapist to practice how to successfully cope with the problem. When the patient is confronted with a similar situation again, the rehearsed behavior will be drawn on to deal with it. The therapist asks the patient a series of questions designed to guide the patient towards the discovery of his or her cognitive distortions. Patients keep a detailed written diary of situations that arise in everyday life, the thoughts and emotions surrounding them, and the behavior that accompany them. In order to encourage self-discovery and reinforce insights made in therapy, the therapist may ask the patient to do homework assignments. These may include note-taking during the session, journaling (see above), review of an audiotape of the patient session, or reading books or articles appropriate to the therapy. They may also be more behaviorally focused, applying a newly learned strategy or coping mechanism to a situation, and then recording the results for the next therapy session. The patient can then model this behavior. Patients may have certain fundamental core beliefs, known as schemas, which are flawed, and are having a negative impact on the patient's behavior and functioning. For example, a patient suffering from depression may develop a social phobia because he/she is convinced he/she is uninteresting and impossible to love. A cognitive-behavioral therapist would test this assumption by asking the patient to name family and friends that care for him/her and enjoy his/her company. By showing the patient that others value him/her, the therapist exposes the irrationality of the patient's assumption and also provides a new model of thought for the patient to change his/her previous behavior pattern (i.e., I am an interesting and likeable person, therefore I should not have any problem making new social acquaintances). Additional behavioral techniques such as conditioning (the use of positive and/or negative reinforcements to encourage desired behavior) and systematic desensitization (gradual exposure to anxiety-producing situations in order to extinguish the fear response) may then be used to gradually reintroduce the patient to social situations. Patients with significant cognitive impairments (e.g., patients with traumatic brain injury or organic brain disease) and individuals who are not willing to take an active role in the treatment process are not usually good candidates. Individuals interested in cognitive therapy should schedule a consultation session with their prospective therapist before starting treatment. During the consultation, the therapist gathers information to make an initial assessment of the patient and to recommend both direction and goals for treatment. The patient has the opportunity to learn about the therapist's professional credentials, his/her approach to treatment, and other relevant issues. In some managed-care settings, an intake interview is required before a patient can meet with a therapist. The intake interview is typically performed by a psychiatric nurse, counselor, or social worker, either face-to-face or over the phone. It is used to gather a brief background on treatment history and make a preliminary evaluation of the patient before assigning them to a therapist. Cognitive and cognitive behavior treatments have been among those therapies not likely to be evaluated, however, and efficacy is well-documented for some symptoms and problems. Prisoners of hate: the cognitive basis of anger, hostility, and violence. Greenberger, Dennis and Christine Padesky. One of the many scary facts of the SRS cases is that the post-surgery injuries took months to manifest, so a nationwide warning went out after perhaps thousands of patients had undergone the procedure. Those claims are handled in exactly the same manner as those in a state having a fault law: looking for your personal collision insurance or by filing a suit from the poor driver. Suits, nevertheless, are allowed for harms matching with a specific threshold, the meaning of which varies greatly on the list of no-fault PIP states. In verbal (illustrative) brink PIP states (see below), harms should be comparatively intense (major loss of use of body part, disfigurement, permanent impairment, bone fracture) or conveyed in relation to duration of impairment (total handicap over 180 days). The registry is the primary area you need to assess. The State won’t, nevertheless, allow you to find your arrival relatives, even though they’ve enrolled. Your birth relatives will simply suggest you whether arrival relatives or adoptees have registered addresses and their names, so they can be located by you. To get a base payment of $500, I am going to recover your file from its safe storage services; evaluation the file to find out in case your arrival relatives consented to some release of the identifying info; and I’ll a satisfy together with you to go over your alternatives, search or contact by means of your birth family. We may have to engage a detective agency if you choose to go looking for the birth family. We do have added way of seeking for the arrival relatives, including court proceedings to open the Broward child adoption file that is first. I’m easing reunions and these investigations in a reduced-fee because I would like to make relatives affordable for all and I consider they work-out really properly in many cases. More focus and scientific research is proving that preoccupied driving behavior leads to injuries and fatalities across U.S. roadways. Nevertheless, even with such a higher percentage of adolescents knowing the dangers, 35 percent of teenagers still text behind the wheel. State actors such as the police are hence required to show probable cause before seizing a person. Due to this fact the right of the fourth amendment is not absolute when it comes to seizing and searching cars. In various occasions, the courts have pointed out that when one is in the car there is a lack of privacy. The fourth amendment right to the driver and passenger during a police stop is valid when a driver is pulled over for a minor traffic infraction. The police officer will only have the right to search the car if he possess a valid search warrant, valid arrest warrant, and a belief of probable cause’ that the driver or the passenger has committed a crime. When one is arrested due to a traffic violation, the police have no mandate to search the car. The police can only search a vehicle after an arrest of a recent occupant unless the police officers have unreasonable doubt that the evidence of an offense is in the car. If the police find probable cause that a car is transporting illicit items such as drugs they are only required to produce a search warrant if the car is stationary. A search will be permissible without a search warrant if\n\n five workmen. The only way to avoid the deaths of these workmen is to hit a switch on your dashboard that will cause the trolley to proceed to the right, causing the death of the single workman. Is it appropriate for you to hit the switch in order to avoid the deaths of the five workmen?'' (Most people judge that it is appropriate to hit the switch in this case.) ''The Footbridge Case: “A runaway trolley is heading down the tracks toward five workmen who will be killed if the trolley proceeds on its present course. Then in January 2003, a large group of police officers called at his door. The police officers had said, \"We are from the El Segundo Police Department, and the Los Angeles County Sheriff's Department.\" The police officers then told him that they were there because of the murders of two police officers in 1957. Horrified, Mason responded, \"My god, you're here \n\nHow Does Cognitive Behavioral Therapy Work in Rehab? Someone might think that since they spilled their coffee, the rest of their day will be bad. However, not everyone operates this way. While everyone’s addiction develops for different reasons, many of those who are addicts or alcoholics find that their addictive tendencies developed in response to something negative that occurred within their lives. This can include abuse, neglect, and trauma, all of which can completely alter the way in which one thinks, making it challenging to uphold healthy, positive thinking patterns. It is often negative thinking that leads to further substance abuse and keeps individuals from obtaining the help they need. The same goes for those with a mental health condition, however negative thinking patterns often occur as a direct reflection of the condition that he or she is experiencing. For example, someone who is grappling with a major depressive disorder can struggle significantly with finding the will and the effort to work through negative thinking patterns and adopt positive ones. However, while these types of thinking patterns are common in those who have substance use disorders and/or mental health conditions, there is treatment available that can help break these cycles so that healing can begin. One of the most effective treatments for this problem is cognitive behavioral therapy. When in a treatment setting, an individual can expect these principles to serve as the foundation of their cognitive behavioral therapy. For example, the therapist leading the group therapy session can encourage all clients to share a common negative thought that they have about themselves. As everyone shares that thought, the therapist can guide them to begin altering that thought. In many cases, group members often share the same negative thoughts, which can benefit everyone even more, as they not only focus on the thought that they brought to the table but also the thoughts that they share with others.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: A police officer carries out hundreds of traffic stops every year. When his supervisor is reviewing the officer’s records for the past year, he notices that the officer is equally likely to stop people of various genders, ages, and races. However, he is significantly more likely to write tickets for middle-aged white males with dark hair and eyes. When confronted with this fact, the officer truthfully states that he has no idea why that is, and that it must simply be a coincidence. Unbeknownst to the officer, this behavior is tied to the fact that these men look like his father, with whom he had an abusive relationship as a child. What psychological framework would directly address the unconscious bias in his behavior? \nA. Behaviorist\nB. Psychoanalytic\nC. Cognitive behavioral\nD. Humanistic\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "B. Psychoanalytic",
            "predictions": "B",
            "references": "B"
        },
        "1": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:Also in 2006, the course was changed slightly in the last two miles for the run within the city, providing a route that is less congested with automobile traffic. She became the first member of the 40-year club in 2016 and Zockoll would go on to run in the first 43 St. George Marathons before dying \n\n the first sub-four-minute mile on 6 May 1954 at Oxford University's Iffley Road Track, Chataway and Chris Brasher were his pacemakers. He finished in second place in the 5000 m at the European Athletics Championship of 1954, 12.2 seconds behind the winner Vladimir Kuts, but two weeks later turned the tables at a London v. Moscow athletics competition at White City, setting a world record time of 13 minutes 51.6 seconds. After competing in the 1956 Olympics, Chataway retired from international athletics, though he continued to race for Thames Hare and Hounds. James Nuttall (29 December 1840 – February 1907) was a professional British runner, who broke several records, and is regarded as \"one of the best sprinters and quarter milers in England in the 1860s\". During his thirteen-year career, Nuttall ran 440 yards in 51.5 seconds, and ran the half-mile in a world’s best time of 1:55.5. Born in Reddish, Lancashire, Nuttall was the maternal grandson of mill-owner Issachar Thorp, who was heir to the Thorp dynasty of apothecaries and calico printing factories in Manchester. Described as \"compact, agile and powerful of limb\", Nuttall easily won races ranging from 600 yards to half a mile. In 1859, Nuttall became the \n\n When Sherm Miller, who worked for the St. George City Parks and Recreation Department, returned to St. George after running the Deseret News Marathon in Salt Lake City, he was inspired to host a marathon in St. George. Of the 58 who started the race, only 38 reached the finish line, a finish line on a course that was later \n\n to be 40 yards too short.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: Who set the world record for the mile race in 1886?\nA. R Bannister\nB. S Coe\nC. J DiMaggio\nD. WG George\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The answer to this question is D. WG George. William George George set the world record for the mile race in 1886 with a time of 4:28.",
            "predictions": "D",
            "references": "D"
        },
        "2": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:The olfactory system, responsible for our sense of smell, involves several structures that contribute to odor identification. The primary olfactory cortex (POC), which includes the piriform and entorhinal cortices, is the main cortical area that receives direct projections from the olfactory bulb. From there, the axons of mitral and tufted cells transmit these signals to the primary olfactory cortex. Notably, the olfactory system bypasses the thalamus, but damage to the thalamus can still affect odor identification. This suggests that thalamic connections between the primary olfactory cortex and the orbitofrontal cortex (OFC) are involved in odor identification. These associations explain the link between odor perception and cognitive functions such as memory, motivation, arousal, autonomic activity, digestion, and sex. Overall, the structures involved in the olfactory system, including the olfactory receptors, olfactory bulb, primary olfactory cortex, and connections with other brain regions, work together to facilitate odor identification and contribute to our sense of smell. The axons of the mitral and tufted cells synapse within the primary olfactory cortex (POC) (Fig. Although olfaction is unique in that its initial afferent projections bypass the thalamus, persons with damage to the thalamus can exhibit olfactory deficits, particularly ones of odor identification. Such deficits likely reflect the involvement of thalamic connections between the primary olfactory cortex and the orbitofrontal cortex (OFC), where odor identification occurs. The olfactory nerves then unite into fasciculi, forming a plexus under the mucous membrane and rising in grooves or canals in the ethmoid bone. Additionally, the olfactory system is involved in the process of taste, as the perception of flavors is strongly influenced by the sense of smell. Odorant-binding proteins interact with these cilia \n\n1) volatile (able to float through the air) ; 2) small (less than 5.8 x 10-22 grams) ; 3) hydrophobic (repellant to water) An olfactory sensation is called an odor. For a molecule to trigger olfactory receptor neurons, it must have specific properties. For example, our olfactory detection thresholds can change due to molecules with differing lengths of carbon chains. The sensory system that has the most direct connection to the brain is the olfactory system, which is responsible for our sense of smell. The olfactory system is unique in that it directly connects to the brain without passing through the thalamus, unlike other sensory systems such as vision, hearing, touch, and taste. From the olfactory bulb, the signals are then transmitted to other areas of the brain, including the olfactory cortex, amygdala, and hippocampus, which are involved in processing and interpreting smell. The direct connection between the olfactory system and the brain allows for rapid and efficient processing of odors. Additionally, the olfactory system plays a crucial role in our perception of taste, as taste and smell are closely intertwined. In summary, the olfactory system has the most direct connection to the brain compared to other sensory systems. Its unique pathway allows for quick and intricate processing of smells, affecting our emotions, memories, and even our perception of taste.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: Which of the following statements identifies a chemically based sensory system?\nI. Gustatory system\nII. Auditory system\nIII. Olfactory system\nA. I only\nB. II only\nC. III only\nD. I and III only\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The correct answer is C. III only.\n\nExplanation:\n\n* Gustatory system refers to the senses of taste and flavor, which are detected by taste buds on the tongue and elsewhere in the mouth.\n* Auditory system refers to the senses of hearing and",
            "predictions": "C",
            "references": "D"
        },
        "3": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:This is part of phosphocreatine metabolism. In mitochondria, Adenosine triphosphate (ATP) levels are very high as a result of glycolysis, TCA cycle, oxidative phosphorylation processes, whereas creatine phosphate levels are low. This makes conversion of creatine to phosphocreatine a highly favored reaction. In myofibrils, during exercise (contraction) ADP levels are very high, which favors resynthesis of ATP. Thus, phosphocreatine breaks down to creatine, giving its inorganic phosphate for ATP formation. This is done by the enzyme creatine phosphokinase which transduces energy from the transport molecule of phosphocreatine to the useful molecule for contraction demands, ATP, an action performed by ATPase in the myofibril. The resulting creatine product acts as a signal molecule indicating myofibril contraction and diffuses in the opposite direction of phosphocreatine, back towards the mitochondrial intermembrane space where it can be rephosphorylated by creatine phosphokinase. Due to the high concentration of ATP around the mitrochondrial creatine kinase, it will convert ATP into PCr which will then move back out into the cells cytoplasm to be converted into ATP (by cytoplasmic creatine kinase) to be used as energy for muscle contraction. Once the molecule is ingested it accumulates in muscle cells where it can be phosphorylated, increasing the pool of phosphocreatine available for contractile power before it is depleted and other energy systems must be used. History \nThe idea of the creatine phosphate shuttle was suggested as an explanation for altered blood glucose levels in exercising diabetic patients. With the discovery of the mitochondrial isozyme of creatine kinase which participates in the shuttle, the other isozyme in the cytosol, Samuel Bessman further contributed to the creatine phosphate shuttle and proposed that the reversible properties of the creatine kinase enzyme was why exercise in diabetic patients can imitate the effects of Insulin. This is part of phosphocreatine metabolism. In mitochondria, Adenosine triphosphate (ATP) levels are very high as a result of glycolysis, TCA cycle, oxidative phosphorylation processes, whereas creatine phosphate levels are low. This makes conversion of creatine to phosphocreatine a highly favored reaction. In myofibrils, during exercise (contraction) ADP levels are very high, which favors resynthesis of ATP. Thus, phosphocreatine breaks down to creatine, giving its inorganic phosphate for ATP formation. This is done by the enzyme creatine phosphokinase which transduces energy from the transport molecule of phosphocreatine to the useful molecule for contraction demands, ATP, an action performed by ATPase in the myofibril. The resulting creatine product acts as a signal molecule indicating myofibril contraction and diffuses in the opposite direction of phosphocreatine, back towards the mitochondrial intermembrane space where it can be rephosphorylated by creatine phosphokinase. Due to the high concentration of ATP around the mitrochondrial creatine kinase, it will convert ATP into PCr which will then move back out into the cells cytoplasm to be converted into ATP (by cytoplasmic creatine kinase) to be used as energy for muscle contraction. Once the molecule is ingested it accumulates in muscle cells where it can be phosphorylated, increasing the pool of phosphocreatine available for contractile power before it is depleted and other energy systems must be used. History \nThe idea of the creatine phosphate shuttle was suggested as an explanation for altered blood glucose levels in exercising diabetic patients. With the discovery of the mitochondrial isozyme of creatine kinase which participates in the shuttle, the other isozyme in the cytosol, Samuel Bessman further contributed to the creatine phosphate shuttle and proposed that the reversible properties of the creatine kinase enzyme was why exercise in diabetic patients can imitate the effects of Insulin. Biomolecules\n\nThere are two isoenzymes: one in the intermembrane space of mitochondria and one in the cytosol.23.6).Creatine kinase catalyzes the phosphorylation of creatine and the dephosphorylation of phosphocreatine (see Fig.To make up for the loss of creatinine, the body synthesizes creatine (see Chapter 36).Like ATP, phosphocreatine has a high-energy phosphate bond. In contrast, creatine and phosphocreatine can be present in millimolar concentrations. Phosphocreatine and creatine are primarily found in muscle and in the brain, where phosphocreatine is also the primary form of energy storage. Cr, creatine; PCr, phosphocreatine. Phosphocreatine spontaneously cyclizes to form creatinine (see Fig. There are two isoenzymes: one in the intermembrane space of mitochondria and one in the cytosol.Measurements of creatine kinase in the serum are used to diagnose and follow various muscle diseases.Injury to muscle is accompanied by the release of myocyte contents into the extracellular space and blood.There is a muscle-type (M) and a brain-type (B) creatine kinase in the cytosol.Muscle contains mostly MM dimers; severe exercise or injury may lead to an increased fraction of MB dimers. Gold medal winners Linford Christie in the men's 100-m dash and Sally Gunnell in the women's 400-m hurdles supposedly used creatine supplements.Creatine became a popular supplement after the 1992 Olympics in Barcelona.The increased availability of PCr also lessens reliance on energy transfer from anaerobic glycolysis that results in lactate formation.Once synthesized, creatine is transported via the blood from the liver and kidney to the muscle. About 40% of the total exists as free creatine; the remainder combines readily with phosphate to form phosphocreatine (PCr). This process occurs during the first few seconds of high-intensity exercise, and thus allows time for other more sustained glycogen breakdown and glycolysis to speed up to the required rate. Gold medal winners Linford Christie in the men's 100-m dash and Sally Gunnell in the women's 400-m hurdles supposedly used creatine supplements.Since then, creatine has become one of the most popular ergogenic aids used by athletes worldwide.Creatine is usually marketed in the form of creatine monohydrate.Most studies use a creatine-loading regimen of 20–25 g per day in four portions of 5–6 g each, given at different times of the day for 5–7 days. This is part of phosphocreatine metabolism. In mitochondria, Adenosine triphosphate (ATP) levels are very high as a result of glycolysis, TCA cycle, oxidative phosphorylation processes, whereas creatine phosphate levels are low. This makes conversion of creatine to phosphocreatine a highly favored reaction. In myofibrils, during exercise (contraction) ADP levels are very high, which favors resynthesis of ATP. Thus, phosphocreatine breaks down to creatine, giving its inorganic phosphate for ATP formation. This is done by the enzyme creatine phosphokinase which transduces energy from the transport molecule of phosphocreatine to the useful molecule for contraction demands, ATP, an action performed by ATPase in the myofibril. The resulting creatine product acts as a signal molecule indicating myofibril contraction and diffuses in the opposite direction of phosphocreatine, back towards the mitochondrial intermembrane space where it can be rephosphorylated by creatine phosphokinase. Due to the high concentration of ATP around the mitrochondrial creatine kinase, it will convert ATP into PCr which will then move back out into the cells cytoplasm to be converted into ATP (by cytoplasmic creatine kinase) to be used as energy for muscle contraction. Once the molecule is ingested it accumulates in muscle cells where it can be phosphorylated, increasing the pool of phosphocreatine available for contractile power before it is depleted and other energy systems must be used. History \nThe idea of the creatine phosphate shuttle was suggested as an explanation for altered blood glucose levels in exercising diabetic patients. The change in blood glucose levels were very similar to the alterations that would occur if a diabetic patient would receive a shot of Insulin.It was then proposed that contraction of myofibrils during rigorous exercise freed creatine which imitated the effects of Insulin by consumption of ATP and releasing ADP. With the discovery of the mitochondrial isozyme of creatine kinase which participates in the shuttle, the other isozyme in the cytosol, Samuel Bessman further contributed to the creatine phosphate shuttle and proposed that the reversible properties of the creatine kinase enzyme was why exercise in diabetic patients can imitate the effects of Insulin.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: The complete resynthesis of phosphocreatine after very high intensity exercise normally takes:\nA. about 10 seconds.\nB. about 30 seconds.\nC. about 1 minute.\nD. about 4 minutes.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "A. about 10 seconds.",
            "predictions": "A",
            "references": "D"
        },
        "4": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: A race car attempting to jump a series of 8 buses is set up on a flat track with a ramp at the end. Engineers assigned to the project have determined that, in order to jump the buses, the car must reach a velocity of 130 km/h. If the distance of the track is 50m, at what rate must the car accelerate to reach this velocity?\nA. 13 m/s^2\nB. 26 m/s^2\nC. 7 m/s^2\nD. 17 m/s^2\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "To answer this question, we need to use the concept of kinematics and motion. We can start by using the equation for uniformly accelerated motion, which states that the final velocity (v) of an object is equal to its initial velocity (u)",
            "predictions": "",
            "references": "A"
        },
        "5": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:It is a molecule derived from lysine and methionine, and it is involved in the transport of long-chain fatty acyl-CoAs from the cytosol compartment of muscle cells into the mitochondria, where they undergo beta-oxidation. First, they are activated to acyl-CoA esters by an enzyme called acyl-CoA synthetase, which is located on the outer mitochondrial membrane. However, the inner mitochondrial membrane is impermeable to these acyl-CoA esters. The transported fatty acyl-CoAs can now undergo beta-oxidation, a series of biochemical reactions that generate energy by breaking down these fatty acids. Carnitine's role in transporting the fatty acyl-CoAs into the mitochondria is critical for their oxidation and energy production. This transport mechanism is essential for fatty acid oxidation, which occurs within the mitochondria to produce energy. The fatty acyl-CoA molecules are then converted into carnitine derivatives by an enzyme called carnitine palmitoyltransferase I (CPT-I). Once inside the mitochondrial intermembrane space, long chain acylcarnitines are converted back into fatty acyl-CoA molecules by an enzyme called carnitine palmitoyltransferase II (CPT-II), attached to the inner mitochondrial membrane. Finally, the fatty acyl-CoA molecules can freely move across the inner mitochondrial membrane into the matrix, where fatty acid oxidation takes place. This movement is facilitated by the action of carnitine-acylcarnitine translocase, which shuttles the fatty acyl-CoA molecules in exchange for carnitine molecules. In summary, long chain fatty acids penetrate the inner mitochondrial membrane with the assistance of carnitine derivatives. The carnitine derivatives facilitate the transport of long chain acylcarnitines across the outer mitochondrial membrane, while carnitine-acylcarnitine translocase allows the movement of fatty acyl-CoA molecules across the inner mitochondrial membrane. This process is crucial for fatty acid oxidation and energy production within the mitochondria. ; In order for the acyl-CoA to enter the mitochondrion the carnitine shuttle is used: 1) Acyl-CoA is transferred to the hydroxyl group of carnitine by carnitine palmitoyltransferase I, located on the cytosolic faces of the outer and inner mitochondrial membranes. First, the long-chain fatty acyl group is transferred from Coenzyme A (CoA) to carnitine by an enzyme called carnitine palmitoyltransferase I (CPT-I), located in the outer mitochondrial membrane. The carnitine shuttle is a rate-limiting step in the transport of long-chain fatty acids into the mitochondrial matrix and plays a crucial role in fatty acid beta-oxidation, the major pathway for the catabolism of fatty acids in mitochondria. Through beta-oxidation, long-chain fatty acids are broken down into two-carbon fragments, producing acetyl CoA, NADH, and FADH2. This inhibition helps regulate the transport of fatty acids into mitochondria based on the energy needs of the cell. Reference:\n- Adapted from \"Biochemistry\" by Richard A. Harvey, Denise R. Ferrier (2018)\n\nCarnitine plays a crucial role in the process of beta-oxidation, which is the breakdown of fatty acids for energy production. Long-chain fatty acids, which cannot directly cross the mitochondrial membrane, rely on carnitine for transport. The process starts in the cytoplasm of the cell, where fatty acids are activated and attached to a molecule called coenzyme A (CoA) to form fatty acyl-CoA. Once inside the mitochondria, carnitine transfers the fatty acyl-CoA molecule to an enzyme called carnitine palmitoyltransferase I (CPT-I), located on the inner side of the mitochondrial membrane. After the fatty acyl-carnitine molecule has crossed the mitochondrial inner membrane, the carnitine part is then transferred back to the cytoplasm, and the fatty acyl group is converted back into fatty acyl-CoA through the action of an enzyme called carnitine palmitoyltransferase II (CPT-II). This process allows the fatty acyl-CoA to enter the beta-oxidation pathway within the mitochondria. By assisting in the translocation of fatty acyl-CoA across the mitochondrial inner membrane, carnitine plays a crucial role in energy production through the breakdown of fatty acids.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: Fatty acids are transported into the mitochondria bound to:\nA. thiokinase.\nB. coenzyme A (CoA).\nC. acetyl-CoA.\nD. carnitine.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "D. carnitine.",
            "predictions": "D",
            "references": "D"
        },
        "6": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: Sauna use, sometimes referred to as \"sauna bathing,\" is characterized by short-term passive exposure to extreme heat. This exposure elicits mild hyperthermia – an increase in the body's core temperature – that induces a thermoregulatory response involving neuroendocrine, cardiovascular, and cytoprotective mechanisms that work together to restore homeostasis and condition the body for future heat stressors… In recent decades, sauna bathing has emerged as a means to increase lifespan and improve overall health, based on compelling data from observational, interventional, and mechanistic studies. Of particular interest are the findings from studies of participants in the Kuopio Ischemic Heart Disease Risk Factor (KIHD) Study, an ongoing prospective population-based cohort study of health outcomes in more than 2,300 middle-aged men from eastern Finland, which identified strong links between sauna use and reduced death and disease… The KIHD findings showed that men who used the sauna two to three times per week were 27 percent less likely to die from cardiovascular-related causes than men who didn't use the sauna.[2] Furthermore, the benefits they experienced were found to be dose-dependent: Men who used the sauna roughly twice as often, about four to seven times per week, experienced roughly twice the benefits – and were 50 percent less likely to die from cardiovascular-related causes.[2] In addition, frequent sauna users were found to be 40 percent less likely to die from all causes of premature death. These findings held true even when considering age, activity levels, and lifestyle factors that might have influenced the men's health.[2]... The KIHD also revealed that frequent sauna use reduced the risk of developing dementia and Alzheimer's disease in a dose-dependent manner. Men who used the sauna two to three times per week had a 66 percent lower risk of developing dementia and a 65 percent lower risk of developing Alzheimer's disease, compared to men who used the sauna only one time per week… The health benefits associated with sauna use extended to other aspects of mental health, as well. Men participating in the KIHD study who used the sauna four to seven times per week were 77 percent less likely to develop psychotic disorders, regardless of the men's dietary habits, socioeconomic status, physical activity, and inflammatory status (as measured by C-reactive protein)…Exposure to high temperature stresses the body, eliciting a rapid, robust response. The skin and core body temperatures increase markedly, and sweating ensues. The skin heats first, rising to 40°C (104°F), and then changes in core body temperature occur, rising slowly from 37°C (98.6°F, or normal) to 38°C (100.4°F) and then rapidly increasing to 39°C (102.2°F)…  Cardiac output, a measure of the amount of work the heart performs in response to the body's need for oxygen, increases by 60 to 70 percent, while the heart rate (the number of beats per minute) increases and the stroke volume (the amount of blood pumped) remains unchanged.[5] During this time, approximately 50 to 70 percent of the body's blood flow is redistributed from the core to the skin to facilitate sweating. The average person loses approximately 0.5 kg of sweat while sauna bathing.[11] Acute heat exposure also induces a transient increase in overall plasma volume to mitigate the decrease in core blood volume. This increase in plasma volume not only provides a reserve source of fluid for sweating, but it also acts like the water in a car's radiator, cooling the body to prevent rapid increases in core body temperature and promoting heat tolerance… Repeated sauna use acclimates the body to heat and optimizes the body's response to future exposures, likely due to a biological phenomenon known as hormesis, a compensatory defense response following exposure to a mild stressor that is disproportionate to the magnitude of the stressor. Hormesis triggers a vast array of protective mechanisms that not only repair cell damage but also provide protection from subsequent exposures to more devastating stressors… The physiological responses to sauna use are remarkably similar to those experienced during moderate- to vigorous-intensity exercise. In fact, sauna use has been proposed as an alternative to exercise for people who are unable to engage in physical activity due to chronic disease or physical limitations.[13]\n\nBased on the article, which of the following statements is the author likely to agree with?\nA. Heart surgery patients who cannot run on treadmills may benefit from sauna use.\nB. Patients on a diet would benefit from sauna use.\nC. Salt restriction would be equal to sauna use for hypertensive patients.\nD. Patients with skin conditions may be cured with sauna use.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "A. Heart surgery patients who cannot run on treadmills may benefit from sauna use.\n\nThe article suggests that sauna use can reduce the risk of cardiovascular-related deaths and improve overall health, particularly in individuals who engage in regular sauna use. It also mentions",
            "predictions": "A",
            "references": "A"
        },
        "7": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:By binding to enzymes' active sites, inhibitors reduce the compatibility of substrate and enzyme and this leads to the inhibition of Enzyme-Substrate complexes' formation, preventing the catalysis of reactions and decreasing (at times to zero) the amount of product produced by a reaction. It can be said that as the concentration of enzyme inhibitors increases, the rate of enzyme activity decreases, and thus, the amount of product produced is inversely proportional to the concentration of inhibitor molecules. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all molecules that bind to enzymes are inhibitors; enzyme activators bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme. The binding of an inhibitor can stop a substrate from entering the enzyme's active site and/or hinder the enzyme from catalyzing its reaction. These inhibitors modify key amino acid residues needed for enzymatic activity. Natural enzyme inhibitors can also be poisons and are used as defenses against predators or as ways of killing prey. Reversible inhibitors Types of reversible inhibitors Reversible inhibitors attach to enzymes with non-covalent interactions such as hydrogen bonds, hydrophobic interactions and ionic bonds. Multiple weak bonds between the inhibitor and the active site combine to produce strong and specific binding. In competitive inhibition, the substrate and inhibitor cannot bind to the enzyme at the same time, as shown in the figure on the right. This usually results from the inhibitor having an affinity for the active site of an enzyme where the substrate also binds; the substrate and inhibitor compete for access to the enzyme's active site. This type of inhibition can be overcome by sufficiently high concentrations of substrate (Vmax remains constant), i.e., by out-competing the inhibitor. In uncompetitive inhibition, the inhibitor binds only to the enzyme-substrate complex. This type of inhibition causes Vmax to decrease (maximum velocity decreases as a result of removing activated complex) and Km to decrease (due to better binding efficiency as a result of Le Chatelier's principle and the effective elimination of the ES complex thus decreasing the Km which indicates a higher binding affinity). Although it is possible for mixed-type inhibitors to bind in the active site, this type of inhibition generally results from an allosteric effect where the inhibitor binds to a different site on an enzyme. For competitive inhibition the degree of inhibition is reduced by increasing [S], for noncompetitive inhibition the degree of inhibition is unchanged, and for uncompetitive (also called anticompetitive) inhibition the degree of inhibition increases with [S]. Quantitative description of reversible inhibition Reversible inhibition can be described quantitatively in terms of the inhibitor's binding to the enzyme and to the enzyme-substrate complex, and its effects on the kinetic constants of the enzyme. {| | Competitive inhibitors can bind to E, but not to ES. Competitive inhibition increases Km (i.e., the inhibitor interferes with substrate binding), but does not affect Vmax (the inhibitor does not hamper catalysis in ES because it cannot bind to ES). Uncompetitive inhibitors bind to ES. Uncompetitive inhibition decreases both Km' and 'Vmax. The inhibitor affects substrate binding by increasing the enzyme's affinity for the substrate (decreasing Km) as well as hampering catalysis (decreases Vmax). Mixed-type inhibitors bind to both E and ES, but their affinities for these two forms of the enzyme are different (Ki ≠ Ki'). Thus, mixed-type inhibitors affect substrate binding (increase or decrease Km) and hamper catalysis in the ES complex (decrease Vmax). Hence, Ki' is usually measured indirectly, by observing the enzyme activity under various substrate and inhibitor concentrations, and fitting the data to a modified Michaelis–Menten equation where the modifying factors α and α' are defined by the inhibitor concentration and its two dissociation constants Thus, in the presence of the inhibitor, the enzyme's effective Km and Vmax become (α/α')Km and (1/α')Vmax, respectively. The effects of different types of reversible enzyme inhibitors on enzymatic activity can be visualized using graphical representations of the\n\nAn enzyme inhibitor is a molecule that binds to an enzyme and decreases its activity. By binding to enzymes' active sites, inhibitors reduce the compatibility of substrate and enzyme and this leads to the inhibition of Enzyme-Substrate complexes' formation, preventing the catalysis of reactions and decreasing (at times to zero) the amount of product produced by a reaction. It can be said that as the concentration of enzyme inhibitors increases, the rate of enzyme activity decreases, and thus, the amount of product produced is inversely proportional to the concentration of inhibitor molecules. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all molecules that bind to enzymes are inhibitors; enzyme activators bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme. The binding of an inhibitor can stop a substrate from entering the enzyme's active site and/or hinder the enzyme from catalyzing its reaction. These inhibitors modify key amino acid residues needed for enzymatic activity. Natural enzyme inhibitors can also be poisons and are used as defenses against predators or as ways of killing prey. Reversible inhibitors Types of reversible inhibitors Reversible inhibitors attach to enzymes with non-covalent interactions such as hydrogen bonds, hydrophobic interactions and ionic bonds. Multiple weak bonds between the inhibitor and the active site combine to produce strong and specific binding. In competitive inhibition, the substrate and inhibitor cannot bind to the enzyme at the same time, as shown in the figure on the right. This usually results from the inhibitor having an affinity for the active site of an enzyme where the substrate also binds; the substrate and inhibitor compete for access to the enzyme's active site. This type of inhibition can be overcome by sufficiently high concentrations of substrate (Vmax remains constant), i.e., by out-competing the inhibitor. In uncompetitive inhibition, the inhibitor binds only to the enzyme-substrate complex. This type of inhibition causes Vmax to decrease (maximum velocity decreases as a result of removing activated complex) and Km to decrease (due to better binding efficiency as a result of Le Chatelier's principle and the effective elimination of the ES complex thus decreasing the Km which indicates a higher binding affinity). Although it is possible for mixed-type inhibitors to bind in the active site, this type of inhibition generally results from an allosteric effect where the inhibitor binds to a different site on an enzyme. For competitive inhibition the degree of inhibition is reduced by increasing [S], for noncompetitive inhibition the degree of inhibition is unchanged, and for uncompetitive (also called anticompetitive) inhibition the degree of inhibition increases with [S]. Quantitative description of reversible inhibition Reversible inhibition can be described quantitatively in terms of the inhibitor's binding to the enzyme and to the enzyme-substrate complex, and its effects on the kinetic constants of the enzyme. {| | Competitive inhibitors can bind to E, but not to ES. Competitive inhibition increases Km (i.e., the inhibitor interferes with substrate binding), but does not affect Vmax (the inhibitor does not hamper catalysis in ES because it cannot bind to ES). Uncompetitive inhibitors bind to ES. Uncompetitive inhibition decreases both Km' and 'Vmax. The inhibitor affects substrate binding by increasing the enzyme's affinity for the substrate (decreasing Km) as well as hampering catalysis (decreases Vmax). Mixed-type inhibitors bind to both E and ES, but their affinities for these two forms of the enzyme are different (Ki ≠ Ki'). Thus, mixed-type inhibitors affect substrate binding (increase or decrease Km) and hamper catalysis in the ES complex (decrease Vmax). Hence, Ki' is usually measured indirectly, by observing the enzyme activity under various substrate and inhibitor concentrations, and fitting the data to a modified Michaelis–Menten equation where the modifying factors α and α' are defined by the inhibitor concentration and its two dissociation constants Thus, in the presence of the inhibitor, the enzyme's effective Km and Vmax become (α/α')Km and (1/α')Vmax, respectively. In these cases, it is usually more practical to treat the tight-binding inhibitor as an irreversible inhibitor (see below); however, it can still be possible to estimate Ki' kinetically if Ki is measured independently. The effects of different types of reversible enzyme inhibitors on enzymatic activity can be visualized using graphical representations of the\n\nDCPIP (blue) + H+   →    DCPIPH (pink) ; DCPIPH (pink) + vitamin C → DCPIPH2 (colorless) 2,6-Dichlorophenolindophenol (DCPIP, DCIP or DPIP) is a chemical compound used as a redox dye. When oxidized, DCPIP is blue with a maximal absorption at 600 nm; when reduced, DCPIP is colorless. DCPIP has a higher affinity for electrons than ferredoxin and the photosynthetic electron transport chain can reduce DCPIP as a substitute for NADP+, that is normally the final electron carrier in photosynthesis. These types of pesticides can also directly interact with the biochemical receptors of acetylcholine. Organophosphates in general poisons mammals and insects by phosphorylating the acetylcholinesterase enzyme at nerve endings resulting in loss of function of the enzyme. This allows the accumulation of the neurotransmitter acetylcholine in cholinergic neuroeffector junctions, skeletal myoneural junctions, and autonomic ganglia. This refers to the type of receptors of acetylcholine, the muscarinic and nicotinic effects respectively. Thus organophosphates also impairs nerve impulse transmission. By binding to enzymes' active sites, inhibitors reduce the compatibility of substrate and enzyme and this leads to the inhibition of Enzyme-Substrate complexes' formation, preventing the catalysis of reactions and decreasing (at times to zero) the amount of product produced by a reaction. It can be said that as the concentration of enzyme inhibitors increases, the rate of enzyme activity decreases, and thus, the amount of product produced is inversely proportional to the concentration of inhibitor molecules. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all molecules that bind to enzymes are inhibitors; enzyme activators bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme. The binding of an inhibitor can stop a substrate from entering the enzyme's active site and/or hinder the enzyme from catalyzing its reaction. These inhibitors modify key amino acid residues needed for enzymatic activity. Natural enzyme inhibitors can also be poisons and are used as defenses against predators or as ways of killing prey. Reversible inhibitors Types of reversible inhibitors Reversible inhibitors attach to enzymes with non-covalent interactions such as hydrogen bonds, hydrophobic interactions and ionic bonds. Multiple weak bonds between the inhibitor and the active site combine to produce strong and specific binding. In competitive inhibition, the substrate and inhibitor cannot bind to the enzyme at the same time, as shown in the figure on the right. This usually results from the inhibitor having an affinity for the active site of an enzyme where the substrate also binds; the substrate and inhibitor compete for access to the enzyme's active site. This type of inhibition can be overcome by sufficiently high concentrations of substrate (Vmax remains constant), i.e., by out-competing the inhibitor. In uncompetitive inhibition, the inhibitor binds only to the enzyme-substrate complex. This type of inhibition causes Vmax to decrease (maximum velocity decreases as a result of removing activated complex) and Km to decrease (due to better binding efficiency as a result of Le Chatelier's principle and the effective elimination of the ES complex thus decreasing the Km which indicates a higher binding affinity). Although it is possible for mixed-type inhibitors to bind in the active site, this type of inhibition generally results from an allosteric effect where the inhibitor binds to a different site on an enzyme. For competitive inhibition the degree of inhibition is reduced by increasing [S], for noncompetitive inhibition the degree of inhibition is unchanged, and for uncompetitive (also called anticompetitive) inhibition the degree of inhibition increases with [S]. Quantitative description of reversible inhibition Reversible inhibition can be described quantitatively in terms of the inhibitor's binding to the enzyme and to the enzyme-substrate complex, and its effects on the kinetic constants of the enzyme. {| | Competitive inhibitors can bind to E, but not to ES. Competitive inhibition increases Km (i.e., the inhibitor interferes with substrate binding), but does not affect Vmax (the inhibitor does not hamper catalysis in ES because it cannot bind to ES). Uncompetitive inhibitors bind to ES. Uncompetitive inhibition decreases both Km' and 'Vmax. The inhibitor affects substrate binding by increasing the enzyme's affinity for the substrate (decreasing Km) as well as hampering catalysis (decreases Vmax). Mixed-type inhibitors bind to both E and ES, but their affinities for these two forms of the enzyme are different (Ki ≠ Ki'). Thus, mixed-type inhibitors affect substrate binding (increase or decrease Km) and hamper catalysis in the ES complex (decrease Vmax). Hence, Ki' is usually measured indirectly, by observing the enzyme activity under various substrate and inhibitor concentrations, and fitting the data to a modified Michaelis–Menten equation where the modifying factors α and α' are defined by the inhibitor concentration and its two dissociation constants Thus, in the presence of the inhibitor, the enzyme's effective Km and Vmax become (α/α')Km and (1/α')Vmax, respectively. In these cases, it is usually more practical to treat the tight-binding inhibitor as an irreversible inhibitor (see below); however, it can still be possible to estimate Ki' kinetically if Ki is measured independently. The effects of different types of reversible enzyme inhibitors on enzymatic activity can be visualized using graphical representations of the\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: Diisopropylfluorophosphate (DFP) binds to the active site of acetylcholinesterase (ACE) in the synapses of neurons. When DFP binds to ACE, the ACE enzyme is rendered permanently inactive. This makes DFP a potent toxin, with lethal amounts at less than 100 mg. The interaction between DFP and ACE can best be characterized as:\nA. Competitive inhibition\nB. Noncompetitive inhibition\nC. Irreversible inhibition\nD. Partially competitive inhibition\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The answer to the question is C. Irreversible inhibition.\n\nExplanation:\n\nDiisopropylfluorophosphate (DFP) is a potent toxin that binds irreversibly to the active site of acetylcholinesterase (ACE",
            "predictions": "C",
            "references": "C"
        },
        "8": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: The process of translation requires the presence of:\nA. mRNA, tRNA and ribosomes.\nB. mRNA, ribosomes and RNA polymerase.\nC. DNA, mRNA and RNA polymerase.\nD. chromatin, DNA and amino acids.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The correct answer is A. mRNA, tRNA, and ribosomes.\n\nTranslation is the process by which the genetic information encoded in messenger RNA (mRNA) is used to synthesize proteins. It involves three main steps: initiation, elongation,",
            "predictions": "A",
            "references": "A"
        },
        "9": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:Fluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, breast cancer in women, and anemia. The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization. In addition to its medical use, fluoxymesterone is used to improve physique and performance. Medical uses\nFluoxymesterone is or has been used in the treatment of hypogonadism, delayed puberty, and anemia in males and the treatment of breast cancer in women. It is specifically approved in one or more countries for the treatment of hypogonadism in men, delayed puberty in boys, and breast cancer in women. Fluoxymesterone is less effective in inducing masculinization than testosterone, but is useful for maintaining established masculinization in adults. Non-medical uses\nFluoxymesterone is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. Pharmacology\n\nPharmacodynamics\n\nAs an AAS, fluoxymesterone is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and DHT. As such, fluoxymesterone has a relatively poor ratio of anabolic to androgenic activity similarly to testosterone and methyltestosterone. However, fluoxymesterone is nonetheless proportionally less androgenic and more anabolic than methyltestosterone and testosterone. Fluoxymesterone has been reported to be non-aromatizable due to steric hindrance by its C11β hydroxyl group, and hence is not considered to have a propensity for producing estrogenic effects such as gynecomastia or fluid retention. However, paradoxically, a case report of severe fluoxymesterone-induced gynecomastia exists, and gynecomastia associated with fluoxymesterone has also been reported in other publications, although this may not be due to estrogenic activity. 11β-HSD inhibition\nFluoxymesterone has been found to act as a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) ( = 60–630 nM), with a potency comparable to that of the 11β-HSD2 inhibitor glycyrrhetinic acid. This action of fluoxymesterone is unique among AAS and is likely related to its 11β-hydroxyl group. Inhibition of 11β-HSD2 by fluoxymesterone may result in mineralocorticoid receptor overactivation and associated side effects such as hypertension and fluid retention, and has been hypothesized to be involved in the cardiovascular and other adverse effects of fluoxymesterone. Glucocorticoid activity\nUnlike other AAS, fluoxymesterone has structural features in common with corticosteroids, including its C9α fluoro and C11β hydroxyl groups. Pharmacokinetics\nFluoxymesterone has approximately 80% oral bioavailability, unlike testosterone, as the C17α methyl group of fluoxymesterone inhibits first-pass metabolism. Chemistry\n\nFluoxymesterone, also known as 9α-fluoro-11β-hydroxy-17α-methyltestosterone or as 9α-fluoro-17α-methylandrost-4-en-11β,17β-diol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of testosterone (androst-4-en-17β-ol-3-one). It is specifically the derivative of testosterone with a fluorine atom at the C9α position, a hydroxyl group at the C11β position, and a methyl group at the C17α position. Synthesis\nStep one: The first step in the synthesis of fluoxymesterone is the microbiological oxidation of commercially available androstenedione (1.11) by Actinomyces; this introduces a hydroxyl group to the 11α-position (1.12), which is then oxidised to a ketone using Jones' reagent, yielding the 3,11,17-triketone, adrenosterone (1.13). Step two: The 11α-hydroxyl of the starting material (1.16) is sulfonylated by p-toluenesulfonyl chloride; addition of trimethylamine (base) deprotonates the 11α-carbon, yielding an (E2) elimination of tosylate (pka - 5) to give olefin (1.17). The resulting structure (1.20) is the androgenic steroid, fluoxymesterone. Detection in body fluids\nDetection of halotestin and other such illegal anabolic steroids in sports is achieved by GS-MS identification of urinary excreted anabolic steroids and their metabolites. The others (as of November 2017) are testosterone, testosterone cypionate, testosterone enanthate, testosterone undecanoate, methyltestosterone, oxandrolone, and oxymetholone. References\n\nExternal links\n\n11β-Hydroxysteroid dehydrogenase inhibitors\nAndrogens and anabolic steroids\nAndrostanes\nDiols\nGlucocorticoids\nHepatotoxins\nHormonal antineoplastic drugs\nEnones\nOrganofluorides\nWorld Anti-Doping Agency prohibited substances\n\nFluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, breast cancer in women, and anemia. The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization. In addition to its medical use, fluoxymesterone is used to improve physique and performance. Medical uses\nFluoxymesterone is or has been used in the treatment of hypogonadism, delayed puberty, and anemia in males and the treatment of breast cancer in women. It is specifically approved in one or more countries for the treatment of hypogonadism in men, delayed puberty in boys, and breast cancer in women. Fluoxymesterone is less effective in inducing masculinization than testosterone, but is useful for maintaining established masculinization in adults. Non-medical uses\nFluoxymesterone is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. Pharmacology\n\nPharmacodynamics\n\nAs an AAS, fluoxymesterone is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and DHT. As such, fluoxymesterone has a relatively poor ratio of anabolic to androgenic activity similarly to testosterone and methyltestosterone. However, fluoxymesterone is nonetheless proportionally less androgenic and more anabolic than methyltestosterone and testosterone. Fluoxymesterone has been reported to be non-aromatizable due to steric hindrance by its C11β hydroxyl group, and hence is not considered to have a propensity for producing estrogenic effects such as gynecomastia or fluid retention. However, paradoxically, a case report of severe fluoxymesterone-induced gynecomastia exists, and gynecomastia associated with fluoxymesterone has also been reported in other publications, although this may not be due to estrogenic activity. 11β-HSD inhibition\nFluoxymesterone has been found to act as a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) ( = 60–630 nM), with a potency comparable to that of the 11β-HSD2 inhibitor glycyrrhetinic acid. This action of fluoxymesterone is unique among AAS and is likely related to its 11β-hydroxyl group. Inhibition of 11β-HSD2 by fluoxymesterone may result in mineralocorticoid receptor overactivation and associated side effects such as hypertension and fluid retention, and has been hypothesized to be involved in the cardiovascular and other adverse effects of fluoxymesterone. Glucocorticoid activity\nUnlike other AAS, fluoxymesterone has structural features in common with corticosteroids, including its C9α fluoro and C11β hydroxyl groups. Pharmacokinetics\nFluoxymesterone has approximately 80% oral bioavailability, unlike testosterone, as the C17α methyl group of fluoxymesterone inhibits first-pass metabolism. Chemistry\n\nFluoxymesterone, also known as 9α-fluoro-11β-hydroxy-17α-methyltestosterone or as 9α-fluoro-17α-methylandrost-4-en-11β,17β-diol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of testosterone (androst-4-en-17β-ol-3-one). It is specifically the derivative of testosterone with a fluorine atom at the C9α position, a hydroxyl group at the C11β position, and a methyl group at the C17α position. Synthesis\nStep one: The first step in the synthesis of fluoxymesterone is the microbiological oxidation of commercially available androstenedione (1.11) by Actinomyces; this introduces a hydroxyl group to the 11α-position (1.12), which is then oxidised to a ketone using Jones' reagent, yielding the 3,11,17-triketone, adrenosterone (1.13). Step two: The 11α-hydroxyl of the starting material (1.16) is sulfonylated by p-toluenesulfonyl chloride; addition of trimethylamine (base) deprotonates the 11α-carbon, yielding an (E2) elimination of tosylate (pka - 5) to give olefin (1.17). The resulting structure (1.20) is the androgenic steroid, fluoxymesterone. Detection in body fluids\nDetection of halotestin and other such illegal anabolic steroids in sports is achieved by GS-MS identification of urinary excreted anabolic steroids and their metabolites. The others (as of November 2017) are testosterone, testosterone cypionate, testosterone enanthate, testosterone undecanoate, methyltestosterone, oxandrolone, and oxymetholone. References\n\nExternal links\n\n11β-Hydroxysteroid dehydrogenase inhibitors\nAndrogens and anabolic steroids\nAndrostanes\nDiols\nGlucocorticoids\nHepatotoxins\nHormonal antineoplastic drugs\nEnones\nOrganofluorides\nWorld Anti-Doping Agency prohibited substances\n\nAnabolic steroids, also known more properly as anabolic–androgenic steroids (AAS), are steroidal androgens that include natural androgens like testosterone as well as synthetic androgens that are structurally related and have similar effects to testosterone. They increase protein within cells, especially in skeletal muscles, and also have varying degrees of virilizing effects, including induction of the development and maintenance of masculine secondary sexual characteristics such as the growth of facial and body hair. The word anabolic, referring to anabolism, comes from the Greek ἀναβολή anabole, \"that which is thrown up, mound\". The American College of Sports Medicine acknowledges that AAS, in the presence of adequate diet, can contribute to increases in body weight, often as lean mass increases and that the gains in muscular strength achieved through high-intensity exercise and proper diet can be additionally increased by the use of AAS in some individuals. These risks are further increased when, as they often do, athletes take steroids alongside other drugs, causing significantly more damage to their bodies. The effect of anabolic steroids on the heart can cause myocardial infarction and strokes. Ergogenic uses for AAS in sports, racing, and bodybuilding as performance-enhancing drugs are controversial because of their adverse effects and the potential to gain unfair advantage in physical competitions. Their use is referred to as doping and banned by most major sporting bodies. Uses Medical Since the discovery and synthesis of testosterone in the 1930s, AAS have been used by physicians for many purposes, with varying degrees of success. These can broadly be grouped into anabolic, androgenic, and other uses. Anabolic Bone marrow stimulation: For decades, AAS were the mainstay of therapy for hypoplastic anemias due to leukemia, kidney failure or aplastic anemia. Growth stimulation: AAS can be used by pediatric endocrinologists to treat children with growth failure. Stimulation of lean body mass and prevention of bone loss in elderly men, as some studies indicate. Counteracting the catabolic effect of long-term corticosteroid therapy. Testosterone is now nearly the only androgen used for this purpose and has been shown to increase height, weight, and fat-free mass in boys with delayed puberty. Testosterone is usually used for this purpose, although methyltestosterone is also used. Enhancing performance Most steroid users are not athletes. \"Among 12- to 17-year-old boys, use of steroids and similar drugs jumped 25 percent from 1999 to 2000, with 20 percent saying they use them for looks rather than sports, a study by insurer Blue Cross Blue Shield found. According to a recent survey, 78.4% of steroid users were noncompetitive bodybuilders and non-athletes, while about 13% reported unsafe injection practices such as reusing needles, sharing needles, and sharing multidose vials, though a 2007 study found that sharing of needles was extremely uncommon among individuals using AAS for non-medical purposes, less than 1%. AAS users tend to research the drugs they are taking more than other controlled-substance users; however, the major sources consulted by steroid users include friends, non-medical handbooks, internet-based forums, blogs, and fitness magazines, which can provide questionable or inaccurate information. Another 2007 study had similar findings, showing that, while 66% of individuals using AAS for non-medical purposes were willing to seek medical supervision for their steroid use, 58% lacked trust in their physicians, 92% felt that the medical community's knowledge of non-medical AAS use was lacking, and 99% felt that the public has an exaggerated view of the side-effects of AAS use. A recent study in the Journal of Health Psychology showed that many users believed that steroids used in moderation were safe. Dosages Available forms The AAS that have been used most commonly in medicine are testosterone and its many esters (but most typically testosterone undecanoate, testosterone enanthate, testosterone cypionate, and testosterone propionate), nandrolone esters (typically nandrolone decanoate and nandrolone phenylpropionate), stanozolol, and metandienone (methandrostenolone). Others that have also been available and used\n\nFluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, breast cancer in women, and anemia. The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization. In addition to its medical use, fluoxymesterone is used to improve physique and performance. Medical uses\nFluoxymesterone is or has been used in the treatment of hypogonadism, delayed puberty, and anemia in males and the treatment of breast cancer in women. It is specifically approved in one or more countries for the treatment of hypogonadism in men, delayed puberty in boys, and breast cancer in women. Fluoxymesterone is less effective in inducing masculinization than testosterone, but is useful for maintaining established masculinization in adults. Non-medical uses\nFluoxymesterone is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. Pharmacology\n\nPharmacodynamics\n\nAs an AAS, fluoxymesterone is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and DHT. As such, fluoxymesterone has a relatively poor ratio of anabolic to androgenic activity similarly to testosterone and methyltestosterone. However, fluoxymesterone is nonetheless proportionally less androgenic and more anabolic than methyltestosterone and testosterone. Fluoxymesterone has been reported to be non-aromatizable due to steric hindrance by its C11β hydroxyl group, and hence is not considered to have a propensity for producing estrogenic effects such as gynecomastia or fluid retention. However, paradoxically, a case report of severe fluoxymesterone-induced gynecomastia exists, and gynecomastia associated with fluoxymesterone has also been reported in other publications, although this may not be due to estrogenic activity. 11β-HSD inhibition\nFluoxymesterone has been found to act as a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) ( = 60–630 nM), with a potency comparable to that of the 11β-HSD2 inhibitor glycyrrhetinic acid. This action of fluoxymesterone is unique among AAS and is likely related to its 11β-hydroxyl group. Inhibition of 11β-HSD2 by fluoxymesterone may result in mineralocorticoid receptor overactivation and associated side effects such as hypertension and fluid retention, and has been hypothesized to be involved in the cardiovascular and other adverse effects of fluoxymesterone. Glucocorticoid activity\nUnlike other AAS, fluoxymesterone has structural features in common with corticosteroids, including its C9α fluoro and C11β hydroxyl groups. Pharmacokinetics\nFluoxymesterone has approximately 80% oral bioavailability, unlike testosterone, as the C17α methyl group of fluoxymesterone inhibits first-pass metabolism. Chemistry\n\nFluoxymesterone, also known as 9α-fluoro-11β-hydroxy-17α-methyltestosterone or as 9α-fluoro-17α-methylandrost-4-en-11β,17β-diol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of testosterone (androst-4-en-17β-ol-3-one). It is specifically the derivative of testosterone with a fluorine atom at the C9α position, a hydroxyl group at the C11β position, and a methyl group at the C17α position. Synthesis\nStep one: The first step in the synthesis of fluoxymesterone is the microbiological oxidation of commercially available androstenedione (1.11) by Actinomyces; this introduces a hydroxyl group to the 11α-position (1.12), which is then oxidised to a ketone using Jones' reagent, yielding the 3,11,17-triketone, adrenosterone (1.13). Step two: The 11α-hydroxyl of the starting material (1.16) is sulfonylated by p-toluenesulfonyl chloride; addition of trimethylamine (base) deprotonates the 11α-carbon, yielding an (E2) elimination of tosylate (pka - 5) to give olefin (1.17). The resulting structure (1.20) is the androgenic steroid, fluoxymesterone. Detection in body fluids\nDetection of halotestin and other such illegal anabolic steroids in sports is achieved by GS-MS identification of urinary excreted anabolic steroids and their metabolites. The others (as of November 2017) are testosterone, testosterone cypionate, testosterone enanthate, testosterone undecanoate, methyltestosterone, oxandrolone, and oxymetholone. References\n\nExternal links\n\n11β-Hydroxysteroid dehydrogenase inhibitors\nAndrogens and anabolic steroids\nAndrostanes\nDiols\nGlucocorticoids\nHepatotoxins\nHormonal antineoplastic drugs\nEnones\nOrganofluorides\nWorld Anti-Doping Agency prohibited substances\n\nFluoxymesterone, sold under the brand names Halotestin and Ultandren among others, is an androgen and anabolic steroid (AAS) medication which is used in the treatment of low testosterone levels in men, delayed puberty in boys, breast cancer in women, and anemia. The drug is a synthetic androgen and anabolic steroid and hence is an agonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has strong androgenic effects and moderate anabolic effects, which make it useful for producing masculinization. In addition to its medical use, fluoxymesterone is used to improve physique and performance. Medical uses\nFluoxymesterone is or has been used in the treatment of hypogonadism, delayed puberty, and anemia in males and the treatment of breast cancer in women. It is specifically approved in one or more countries for the treatment of hypogonadism in men, delayed puberty in boys, and breast cancer in women. Fluoxymesterone is less effective in inducing masculinization than testosterone, but is useful for maintaining established masculinization in adults. Non-medical uses\nFluoxymesterone is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. Pharmacology\n\nPharmacodynamics\n\nAs an AAS, fluoxymesterone is an agonist of the androgen receptor (AR), similarly to androgens like testosterone and DHT. As such, fluoxymesterone has a relatively poor ratio of anabolic to androgenic activity similarly to testosterone and methyltestosterone. However, fluoxymesterone is nonetheless proportionally less androgenic and more anabolic than methyltestosterone and testosterone. Fluoxymesterone has been reported to be non-aromatizable due to steric hindrance by its C11β hydroxyl group, and hence is not considered to have a propensity for producing estrogenic effects such as gynecomastia or fluid retention. However, paradoxically, a case report of severe fluoxymesterone-induced gynecomastia exists, and gynecomastia associated with fluoxymesterone has also been reported in other publications, although this may not be due to estrogenic activity. 11β-HSD inhibition\nFluoxymesterone has been found to act as a potent inhibitor of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) ( = 60–630 nM), with a potency comparable to that of the 11β-HSD2 inhibitor glycyrrhetinic acid. This action of fluoxymesterone is unique among AAS and is likely related to its 11β-hydroxyl group. Inhibition of 11β-HSD2 by fluoxymesterone may result in mineralocorticoid receptor overactivation and associated side effects such as hypertension and fluid retention, and has been hypothesized to be involved in the cardiovascular and other adverse effects of fluoxymesterone. Glucocorticoid activity\nUnlike other AAS, fluoxymesterone has structural features in common with corticosteroids, including its C9α fluoro and C11β hydroxyl groups. Pharmacokinetics\nFluoxymesterone has approximately 80% oral bioavailability, unlike testosterone, as the C17α methyl group of fluoxymesterone inhibits first-pass metabolism. Chemistry\n\nFluoxymesterone, also known as 9α-fluoro-11β-hydroxy-17α-methyltestosterone or as 9α-fluoro-17α-methylandrost-4-en-11β,17β-diol-3-one, is a synthetic androstane steroid and a 17α-alkylated derivative of testosterone (androst-4-en-17β-ol-3-one). It is specifically the derivative of testosterone with a fluorine atom at the C9α position, a hydroxyl group at the C11β position, and a methyl group at the C17α position. Synthesis\nStep one: The first step in the synthesis of fluoxymesterone is the microbiological oxidation of commercially available androstenedione (1.11) by Actinomyces; this introduces a hydroxyl group to the 11α-position (1.12), which is then oxidised to a ketone using Jones' reagent, yielding the 3,11,17-triketone, adrenosterone (1.13). Step two: The 11α-hydroxyl of the starting material (1.16) is sulfonylated by p-toluenesulfonyl chloride; addition of trimethylamine (base) deprotonates the 11α-carbon, yielding an (E2) elimination of tosylate (pka - 5) to give olefin (1.17). The resulting structure (1.20) is the androgenic steroid, fluoxymesterone. Detection in body fluids\nDetection of halotestin and other such illegal anabolic steroids in sports is achieved by GS-MS identification of urinary excreted anabolic steroids and their metabolites. The others (as of November 2017) are testosterone, testosterone cypionate, testosterone enanthate, testosterone undecanoate, methyltestosterone, oxandrolone, and oxymetholone. References\n\nExternal links\n\n11β-Hydroxysteroid dehydrogenase inhibitors\nAndrogens and anabolic steroids\nAndrostanes\nDiols\nGlucocorticoids\nHepatotoxins\nHormonal antineoplastic drugs\nEnones\nOrganofluorides\nWorld Anti-Doping Agency prohibited substances\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: Performance enhancing synthetic steroids are based on the structure of the hormone:\nA. testosterone.\nB. cortisol.\nC. progesterone.\nD. aldosterone.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "A.",
            "predictions": "A",
            "references": "A"
        },
        "10": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:Sulfoxylic acid (H2SO2) (also known as hyposulfurous acid or sulfur dihydroxide ) is an unstable oxoacid of sulfur in an intermediate oxidation state between hydrogen sulfide and dithionous acid. To do this, thiourea dioxide first forms a tautomer, aminoiminomethanesulfinic acid (H2NC(=NH)SO2H, abbreviated AIMS) which breaks apart. Sulfoxylate reacts with formaldehyde to yield a hydroxymethanesulfinate called rongalite:\n\n A perchlorate is a chemical compound containing the perchlorate ion,. The majority of perchlorates are commercially produced salts. Perchlorate contamination in food, water, and other parts of the environment has been studied in the U.S. because of harmful effects on human health. Most perchlorates are colorless solids that are soluble in water. Four perchlorates are of primary commercial interest: ammonium perchlorate (NH4ClO4), perchloric acid (HClO4), potassium perchlorate (KClO4), and sodium perchlorate (NaClO4). Perchlorate is the anion resulting from the dissociation of perchloric acid and its salts upon their dissolution in water. Many perchlorate salts are soluble in non-aqueous solutions. Examples of strong acids are hydrochloric acid (HCl), hydroiodic acid (HI), hydrobromic acid (HBr), perchloric acid (HClO4), nitric acid (HNO3) and sulfuric acid (H2SO4). Examples of superacids are fluoroantimonic acid, magic acid and perchloric acid. While Ka measures the strength of an acid compound, the strength of an aqueous acid solution is measured by pH, which is an indication of the concentration of hydronium in the solution. Strong bases hydrolyze in water almost completely, resulting in the leveling effect.\" Here is a list of several strong bases: The cations of these strong bases appear in the first and second groups of the periodic table (alkali and earth alkali metals). Guanidine is a special case of a species that is exceptionally stable when protonated, analogously to the reason that makes perchloric acid and sulfuric acid very strong acids.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: Perchloric acid (HClO4) is considered one of the stronger acids in existence. Which of the following statements corresponds most accurately with strong acids?\nA. Ka is less than 1\nB. They have an open electron spot on their outer valence rings\nC. They have stable conjugate bases\nD. They remain bound in the presence of water.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The correct answer is C. They have stable conjugate bases.",
            "predictions": "C",
            "references": "C"
        },
        "11": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:This technique was used to investigate the hydrogenation of methylenecyclobutane over titania-supported Rh, Pt, and Pd catalysts. The study revealed that methylenecyclobutane hydrogenation leads to the formation of a mixture of reaction products, including cyclic (1-methylcyclobutene, methylcyclobutane), linear (1-pentene, cis-2-pentene, trans-2-pentene, pentane), and branched (isoprene, 2-methyl-1-butene, 2-methyl-2-butene, isopentane) compounds. At lower temperatures (150-350 °C), the major reaction product was found to be methylcyclobutane. On the other hand, higher temperatures of 450 °C favored the formation of branched products such as isoprene, 2-methyl-1-butene, and 2-methyl-2-butene. The PHIP effects were detected for all reaction products except for methylenecyclobutane isomers 1-methylcyclobutene and isoprene. The PHIP technique provides valuable insights into the reaction mechanism and the pathways through which different products are formed during methylenecyclobutane hydrogenation over supported metal catalysts. ; Chain reaction or Propagation then takes place—the halogen radical abstracts a hydrogen from the alkane to give an alkyl radical. Alkanes react with halogens in a so-called free radical halogenation reaction. The hydrogen atoms of the alkane are progressively replaced by halogen atoms. There are three steps: Experiments have shown that all halogenation produces a mixture of all possible isomers, indicating that all hydrogen atoms are susceptible to reaction. An example can be seen in the monobromination of propane:\n\n in competition with SN1 reactions because they share a common carbocationic intermediate. An example is the pyrolysis of a certain sulfonate ester of menthol: Only reaction product A results from antiperiplanar elimination. ; It is accompanied by carbocationic rearrangement reactions Highly substituted alkyl halides are bulky, limiting the room for the E2 one-step mechanism; therefore, the two-step E1 mechanism is favored. ; Highly substituted carbocations \n\n β-Elimination, with loss of electrofuge and nucleofuge on vicinal carbons, is by far the most common type of elimination. For a carbon center, the result of α-elimination is the formation of a carbene, which includes \"stable carbenes\" such as carbon monoxide or isocyanides. For instance, α-elimination the elements of HCl from chloroform (CHCl3) in the presence of strong base is a classic approach for the generation of dichlorocarbene, :CCl2, as a reactive intermediate. ; It is typically undergone by primary substituted alkyl halides, but is possible with some secondary alkyl halides and other compounds.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: A descript amount of 2-bromobutane is placed into a strong solution of ethanol and allowed to complete a reaction. The result of this reaction produces a major product of 2-butene and a minor product of 1-butene. Which of the following descriptions of the starting compound explains why 2-butene is the major product?\nA. Carbon 3 has less hydrogen atoms\nB. 1-butene rearranges to 2-butene in solution\nC. Ethanol prefers the second carbon in any chain\nD. Cyclic aromatization\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The correct answer is A. Carbon 3 has less hydrogen atoms.\n\nExplanation:\nIn the given reaction, 2-bromobutane undergoes an elimination reaction to form 2-butene and 1-butene as the major and minor products",
            "predictions": "A",
            "references": "A"
        },
        "12": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:People undertaking the walk of shame are understood to have spent the night at the residence of a sexual partner (or perceived sexual partner), particularly a one-night stand. In exhibitionism, the walk of shame may also refer to an exhibitionist walking in public while exposed—either partially or fully naked—and trying to reach a place of safety and privacy. In more extreme cases of edgeplay where \n\n  Deviance or the sociology of deviance explores the actions and/ or behaviors that violate social norms across formally enacted rules (e.g., crime) as well as informal violations of social norms (e.g., rejecting folkways and mores). Although deviance may have a negative connotation, the violation of social norms is not always a negative action; positive deviation exists in some situations. A certain act or behaviour may be viewed as deviant and receive sanctions or punishments within one society and be seen as a normal behaviour in another society. There are two types of major deviant actions: mala in se and mala prohibita. treatment of rape, describing it as strange. She argued that he incorrectly refused to consider \"sympathy for the victim and moral disgust\" as reasons for criminalizing rape. She also criticized his treatment of date rape, writing that it reflected a \"peculiar view of women\", and argued that he was inconsistent by ignoring moral revulsion in his discussion of rape but taking it into account as a relevant factor in his discussion of same-sex marriage. She was unpersuaded by his use of utilitarian arguments, especially in the case of abortion, disagreed with his negative assessment of Christian morality, and faulted him for not \n\n and fails to inform his or her sexual partner. ; Statutory rape where the underage participant(s) give actual consent, but the law-makers of the relevant jurisdiction have determined that people of that age are not legally capable of giving informed consent (not informed\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: A hedonic teenager of wayward morals, in one night, sequentially i) has consensual sexual intercourse with his sister, ii) leaves no tip at the bar, iii) has non-censual sexual relations with an unknown woman, and iv) vomits on the steps to the door of a local church. The teenager has violated society’s norms sequentially (to the greatest degree) on the order of:\nA. mores, mores, the law, mores\nB. taboo, folkways, the law, and taboo\nC. the law, folkways, folkways, and folkways\nD. taboo, folkways, the law, and mores\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The correct answer is D. taboo, folkways, the law, and mores.\n\nExplanation:\n\n* Taboo refers to deeply ingrained cultural beliefs that prohibit certain acts or behaviors. In this scenario, the teenager's sexual encounter with their sister is",
            "predictions": "D",
            "references": "D"
        },
        "13": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: The maximum sustainable power:\nA. usually remains constant during a race.\nB. declines with the distance of the race.\nC. is improved by a high fat diet.\nD. is inversely related to muscle glycogen content.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The correct answer is D. is inversely related to muscle glycogen content.\n\nExplanation: Muscle glycogen content plays an important role in determining an athlete's maximum sustainable power. When muscle glycogen stores are low, the body relies more heavily on ana",
            "predictions": "D",
            "references": "B"
        },
        "14": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:Dopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is a neuromodulatory molecule that plays several important roles in cells. Dopamine constitutes about 80% of the catecholamine content in the brain. In the brain, dopamine functions as a neurotransmitter—a chemical released by neurons (nerve cells) to send signals to other nerve cells. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones. These pathways and cell groups form a dopamine system which is neuromodulatory. In popular culture and media, dopamine is often portrayed as the main chemical of pleasure, but the current opinion in pharmacology is that dopamine instead confers motivational salience; in other words, dopamine signals the perceived motivational prominence (i.e., the desirability or aversiveness) of an outcome, which in turn propels the organism's behavior toward or away from achieving that outcome. Outside the central nervous system, dopamine functions primarily as a local paracrine messenger. Several important diseases of the nervous system are associated with dysfunctions of the dopamine system, and some of the key medications used to treat them work by altering the effects of dopamine. Parkinson's disease, a degenerative condition causing tremor and motor impairment, is caused by a loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra. There is evidence that schizophrenia involves altered levels of dopamine activity, and most antipsychotic drugs used to treat this are dopamine antagonists which reduce dopamine activity. Similar dopamine antagonist drugs are also some of the most effective anti-nausea agents. Restless legs syndrome and attention deficit hyperactivity disorder (ADHD) are associated with decreased dopamine activity. Dopaminergic stimulants can be addictive in high doses, but some are used at lower doses to treat ADHD. Dopamine itself is available as a manufactured medication for intravenous injection: although it cannot reach the brain from the bloodstream, its peripheral effects make it useful in the treatment of heart failure or shock, especially in newborn babies. Although dopamine is also found in many types of food, it is incapable of crossing the blood–brain barrier that surrounds and protects the brain. Deficiency in any required amino acid or cofactor can impair the synthesis of dopamine, norepinephrine, and epinephrine. Degradation Dopamine is broken down into inactive metabolites by a set of enzymes—monoamine oxidase (MAO), catechol-O-methyl transferase (COMT), and aldehyde dehydrogenase (ALDH), acting in sequence. Both isoforms of monoamine oxidase, MAO-A and MAO-B, effectively metabolize dopamine. The two primary metabolic routes that convert dopamine into HVA are: Dopamine → DOPAL → DOPAC → HVA – catalyzed by MAO, ALDH, and COMT respectively Dopamine → 3-Methoxytyramine → HVA – catalyzed by COMT and MAO+ALDH respectively In clinical research on schizophrenia, measurements of homovanillic acid in plasma have been used to estimate levels of dopamine activity in the brain. Functions Cellular effects Dopamine exerts its effects by binding to and activating cell surface receptors. In humans, dopamine has a high binding affinity at dopamine receptors and human trace amine-associated receptor 1 (hTAAR1). Consequently, it is incorrect to describe dopamine itself as either excitatory or inhibitory: its effect on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP. Storage, release, and reuptake Inside the brain, dopamine functions as a neurotransmitter and neuromodulator, and is controlled by a set of mechanisms common to all monoamine neurotransmitters. Dopamine is stored in these vesicles until it is ejected into the synaptic cleft. In most cases, the release of dopamine occurs through a process called exocytosis which is caused by action\n\nDopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is a neuromodulatory molecule that plays several important roles in cells. Dopamine constitutes about 80% of the catecholamine content in the brain. In the brain, dopamine functions as a neurotransmitter—a chemical released by neurons (nerve cells) to send signals to other nerve cells. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones. These pathways and cell groups form a dopamine system which is neuromodulatory. In popular culture and media, dopamine is often portrayed as the main chemical of pleasure, but the current opinion in pharmacology is that dopamine instead confers motivational salience; in other words, dopamine signals the perceived motivational prominence (i.e., the desirability or aversiveness) of an outcome, which in turn propels the organism's behavior toward or away from achieving that outcome. Outside the central nervous system, dopamine functions primarily as a local paracrine messenger. Several important diseases of the nervous system are associated with dysfunctions of the dopamine system, and some of the key medications used to treat them work by altering the effects of dopamine. Parkinson's disease, a degenerative condition causing tremor and motor impairment, is caused by a loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra. There is evidence that schizophrenia involves altered levels of dopamine activity, and most antipsychotic drugs used to treat this are dopamine antagonists which reduce dopamine activity. Similar dopamine antagonist drugs are also some of the most effective anti-nausea agents. Restless legs syndrome and attention deficit hyperactivity disorder (ADHD) are associated with decreased dopamine activity. Dopaminergic stimulants can be addictive in high doses, but some are used at lower doses to treat ADHD. Dopamine itself is available as a manufactured medication for intravenous injection: although it cannot reach the brain from the bloodstream, its peripheral effects make it useful in the treatment of heart failure or shock, especially in newborn babies. Although dopamine is also found in many types of food, it is incapable of crossing the blood–brain barrier that surrounds and protects the brain. Deficiency in any required amino acid or cofactor can impair the synthesis of dopamine, norepinephrine, and epinephrine. Degradation Dopamine is broken down into inactive metabolites by a set of enzymes—monoamine oxidase (MAO), catechol-O-methyl transferase (COMT), and aldehyde dehydrogenase (ALDH), acting in sequence. Both isoforms of monoamine oxidase, MAO-A and MAO-B, effectively metabolize dopamine. The two primary metabolic routes that convert dopamine into HVA are: Dopamine → DOPAL → DOPAC → HVA – catalyzed by MAO, ALDH, and COMT respectively Dopamine → 3-Methoxytyramine → HVA – catalyzed by COMT and MAO+ALDH respectively In clinical research on schizophrenia, measurements of homovanillic acid in plasma have been used to estimate levels of dopamine activity in the brain. Functions Cellular effects Dopamine exerts its effects by binding to and activating cell surface receptors. In humans, dopamine has a high binding affinity at dopamine receptors and human trace amine-associated receptor 1 (hTAAR1). Consequently, it is incorrect to describe dopamine itself as either excitatory or inhibitory: its effect on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP. Storage, release, and reuptake Inside the brain, dopamine functions as a neurotransmitter and neuromodulator, and is controlled by a set of mechanisms common to all monoamine neurotransmitters. Dopamine is stored in these vesicles until it is ejected into the synaptic cleft. In most cases, the release of dopamine occurs through a process called exocytosis which is caused by action\n\nDopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is a neuromodulatory molecule that plays several important roles in cells. Dopamine constitutes about 80% of the catecholamine content in the brain. In the brain, dopamine functions as a neurotransmitter—a chemical released by neurons (nerve cells) to send signals to other nerve cells. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones. These pathways and cell groups form a dopamine system which is neuromodulatory. In popular culture and media, dopamine is often portrayed as the main chemical of pleasure, but the current opinion in pharmacology is that dopamine instead confers motivational salience; in other words, dopamine signals the perceived motivational prominence (i.e., the desirability or aversiveness) of an outcome, which in turn propels the organism's behavior toward or away from achieving that outcome. Outside the central nervous system, dopamine functions primarily as a local paracrine messenger. Several important diseases of the nervous system are associated with dysfunctions of the dopamine system, and some of the key medications used to treat them work by altering the effects of dopamine. Parkinson's disease, a degenerative condition causing tremor and motor impairment, is caused by a loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra. There is evidence that schizophrenia involves altered levels of dopamine activity, and most antipsychotic drugs used to treat this are dopamine antagonists which reduce dopamine activity. Similar dopamine antagonist drugs are also some of the most effective anti-nausea agents. Restless legs syndrome and attention deficit hyperactivity disorder (ADHD) are associated with decreased dopamine activity. Dopaminergic stimulants can be addictive in high doses, but some are used at lower doses to treat ADHD. Dopamine itself is available as a manufactured medication for intravenous injection: although it cannot reach the brain from the bloodstream, its peripheral effects make it useful in the treatment of heart failure or shock, especially in newborn babies. Although dopamine is also found in many types of food, it is incapable of crossing the blood–brain barrier that surrounds and protects the brain. Deficiency in any required amino acid or cofactor can impair the synthesis of dopamine, norepinephrine, and epinephrine. Degradation Dopamine is broken down into inactive metabolites by a set of enzymes—monoamine oxidase (MAO), catechol-O-methyl transferase (COMT), and aldehyde dehydrogenase (ALDH), acting in sequence. Both isoforms of monoamine oxidase, MAO-A and MAO-B, effectively metabolize dopamine. The two primary metabolic routes that convert dopamine into HVA are: Dopamine → DOPAL → DOPAC → HVA – catalyzed by MAO, ALDH, and COMT respectively Dopamine → 3-Methoxytyramine → HVA – catalyzed by COMT and MAO+ALDH respectively In clinical research on schizophrenia, measurements of homovanillic acid in plasma have been used to estimate levels of dopamine activity in the brain. Functions Cellular effects Dopamine exerts its effects by binding to and activating cell surface receptors. In humans, dopamine has a high binding affinity at dopamine receptors and human trace amine-associated receptor 1 (hTAAR1). Consequently, it is incorrect to describe dopamine itself as either excitatory or inhibitory: its effect on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP. Storage, release, and reuptake Inside the brain, dopamine functions as a neurotransmitter and neuromodulator, and is controlled by a set of mechanisms common to all monoamine neurotransmitters. Dopamine is stored in these vesicles until it is ejected into the synaptic cleft. In most cases, the release of dopamine occurs through a process called exocytosis which is caused by action\n\nDopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is a neuromodulatory molecule that plays several important roles in cells. Dopamine constitutes about 80% of the catecholamine content in the brain. In the brain, dopamine functions as a neurotransmitter—a chemical released by neurons (nerve cells) to send signals to other nerve cells. Neurotransmitters are synthesized in specific regions of the brain, but affect many regions systemically. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones. These pathways and cell groups form a dopamine system which is neuromodulatory. In popular culture and media, dopamine is often portrayed as the main chemical of pleasure, but the current opinion in pharmacology is that dopamine instead confers motivational salience; in other words, dopamine signals the perceived motivational prominence (i.e., the desirability or aversiveness) of an outcome, which in turn propels the organism's behavior toward or away from achieving that outcome. Outside the central nervous system, dopamine functions primarily as a local paracrine messenger. Several important diseases of the nervous system are associated with dysfunctions of the dopamine system, and some of the key medications used to treat them work by altering the effects of dopamine. Parkinson's disease, a degenerative condition causing tremor and motor impairment, is caused by a loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra. There is evidence that schizophrenia involves altered levels of dopamine activity, and most antipsychotic drugs used to treat this are dopamine antagonists which reduce dopamine activity. Similar dopamine antagonist drugs are also some of the most effective anti-nausea agents. Restless legs syndrome and attention deficit hyperactivity disorder (ADHD) are associated with decreased dopamine activity. Dopaminergic stimulants can be addictive in high doses, but some are used at lower doses to treat ADHD. Dopamine itself is available as a manufactured medication for intravenous injection: although it cannot reach the brain from the bloodstream, its peripheral effects make it useful in the treatment of heart failure or shock, especially in newborn babies. Although dopamine is also found in many types of food, it is incapable of crossing the blood–brain barrier that surrounds and protects the brain. Deficiency in any required amino acid or cofactor can impair the synthesis of dopamine, norepinephrine, and epinephrine. Degradation Dopamine is broken down into inactive metabolites by a set of enzymes—monoamine oxidase (MAO), catechol-O-methyl transferase (COMT), and aldehyde dehydrogenase (ALDH), acting in sequence. Both isoforms of monoamine oxidase, MAO-A and MAO-B, effectively metabolize dopamine. The two primary metabolic routes that convert dopamine into HVA are: Dopamine → DOPAL → DOPAC → HVA – catalyzed by MAO, ALDH, and COMT respectively Dopamine → 3-Methoxytyramine → HVA – catalyzed by COMT and MAO+ALDH respectively In clinical research on schizophrenia, measurements of homovanillic acid in plasma have been used to estimate levels of dopamine activity in the brain. Functions Cellular effects Dopamine exerts its effects by binding to and activating cell surface receptors. In humans, dopamine has a high binding affinity at dopamine receptors and human trace amine-associated receptor 1 (hTAAR1). Consequently, it is incorrect to describe dopamine itself as either excitatory or inhibitory: its effect on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP. Storage, release, and reuptake Inside the brain, dopamine functions as a neurotransmitter and neuromodulator, and is controlled by a set of mechanisms common to all monoamine neurotransmitters. Dopamine is stored in these vesicles until it is ejected into the synaptic cleft. In most cases, the release of dopamine occurs through a process called exocytosis which is caused by action\n\nDopamine (DA, a contraction of 3,4-dihydroxyphenethylamine) is a neuromodulatory molecule that plays several important roles in cells. Dopamine constitutes about 80% of the catecholamine content in the brain. In the brain, dopamine functions as a neurotransmitter—a chemical released by neurons (nerve cells) to send signals to other nerve cells. Neurotransmitters are synthesized in specific regions of the brain, but affect many regions systemically. The brain includes several distinct dopamine pathways, one of which plays a major role in the motivational component of reward-motivated behavior. The anticipation of most types of rewards increases the level of dopamine in the brain, and many addictive drugs increase dopamine release or block its reuptake into neurons following release. Other brain dopamine pathways are involved in motor control and in controlling the release of various hormones. These pathways and cell groups form a dopamine system which is neuromodulatory. In popular culture and media, dopamine is often portrayed as the main chemical of pleasure, but the current opinion in pharmacology is that dopamine instead confers motivational salience; in other words, dopamine signals the perceived motivational prominence (i.e., the desirability or aversiveness) of an outcome, which in turn propels the organism's behavior toward or away from achieving that outcome. Outside the central nervous system, dopamine functions primarily as a local paracrine messenger. Several important diseases of the nervous system are associated with dysfunctions of the dopamine system, and some of the key medications used to treat them work by altering the effects of dopamine. Parkinson's disease, a degenerative condition causing tremor and motor impairment, is caused by a loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra. There is evidence that schizophrenia involves altered levels of dopamine activity, and most antipsychotic drugs used to treat this are dopamine antagonists which reduce dopamine activity. Similar dopamine antagonist drugs are also some of the most effective anti-nausea agents. Restless legs syndrome and attention deficit hyperactivity disorder (ADHD) are associated with decreased dopamine activity. Dopaminergic stimulants can be addictive in high doses, but some are used at lower doses to treat ADHD. Dopamine itself is available as a manufactured medication for intravenous injection: although it cannot reach the brain from the bloodstream, its peripheral effects make it useful in the treatment of heart failure or shock, especially in newborn babies. Although dopamine is also found in many types of food, it is incapable of crossing the blood–brain barrier that surrounds and protects the brain. Deficiency in any required amino acid or cofactor can impair the synthesis of dopamine, norepinephrine, and epinephrine. Degradation Dopamine is broken down into inactive metabolites by a set of enzymes—monoamine oxidase (MAO), catechol-O-methyl transferase (COMT), and aldehyde dehydrogenase (ALDH), acting in sequence. Both isoforms of monoamine oxidase, MAO-A and MAO-B, effectively metabolize dopamine. The two primary metabolic routes that convert dopamine into HVA are: Dopamine → DOPAL → DOPAC → HVA – catalyzed by MAO, ALDH, and COMT respectively Dopamine → 3-Methoxytyramine → HVA – catalyzed by COMT and MAO+ALDH respectively In clinical research on schizophrenia, measurements of homovanillic acid in plasma have been used to estimate levels of dopamine activity in the brain. Functions Cellular effects Dopamine exerts its effects by binding to and activating cell surface receptors. In humans, dopamine has a high binding affinity at dopamine receptors and human trace amine-associated receptor 1 (hTAAR1). Consequently, it is incorrect to describe dopamine itself as either excitatory or inhibitory: its effect on a target neuron depends on which types of receptors are present on the membrane of that neuron and on the internal responses of that neuron to the second messenger cAMP. Storage, release, and reuptake Inside the brain, dopamine functions as a neurotransmitter and neuromodulator, and is controlled by a set of mechanisms common to all monoamine neurotransmitters. Dopamine is stored in these vesicles until it is ejected into the synaptic cleft. In most cases, the release of dopamine occurs through a process called exocytosis which is caused by action\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: A patient comes into the ER looking extremely agitated. They are acting aggressive, and claiming they need medication or “bad things will happen”. What is the likely state of this patient’s dopamine system?\nA. There is decreased dopamine in the synaptic cleft.\nB. There are decreased dopamine receptors on the post-synaptic membrane.\nC. There is cell death in the areas with high dopamine cells.\nD. There is seizure-like activity in the dopamine brain areas.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "A. There is decreased dopamine in the synaptic cleft.\n\nConfidence: 90%\n\nExplanation:\n\nThe patient's symptoms suggest that there may be a decrease in dopamine levels in their brain, leading to agitation, aggression, and hallucinations. This could",
            "predictions": "A",
            "references": "B"
        },
        "15": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:Apoptotic cell death, including that of hair cells and spiral ganglion neurons (SGNs) in the cochlea has been proposed to be the classic theory behind the development of AHL. We hypothesized that the apoptotic pathway may be blocked through the inhibition of T-type Ca2+ channels in cochlear cells in NOD/LtJ mice. Following treatment, auditory-evoked brainstem response (ABR) thresholds and distortion product oto-acoustic emission (DPOAE) of the mice in the 2 groups were measured at different time points. Hair cell and SGN was were significantly lower and auditory function was significantly improved in the ethosuximide-treated group compared to the untreated group. Our data thus indicate that ethosuximide prevents the degeneration of cochlear cells by regulating the expression of genes in apoptotic pathways. Environmental and other factors, such as endocrine disease and ototoxic drugs may contribute to the development of AHL. Sensorineural hearing loss is characterized by a difficulty in hearing high frequencies and is caused by the degeneration of hair cells and spiral ganglion neurons (SGNs). Unfortunately, hair cells and SGNs are non-renewable; hence, their impairment results in decreased hearing sensitivity (5,27). The major contributor to the difference in hearing loss onset time between NOD/LtJ and C57BL/6J mice is the Ahl2 locus on mouse chromosome (Chr)5 in NOD/LtJ mice (6). NOD/LtJ mice exhibit hearing loss before 3 months, and this is much earlier than C57BL/6J mice, which do not exhibit hearing loss until 10 months of age or older (6). This study aimed to evaluate the otoprotective effects of ethosuximide as a Ca2+ channel blocker in NOD/LtJ mice with AHL. In addition, erythropoietin (EPO) can protect against hearing loss in Cdh23erl/erl mice through apoptosis-related pathways (16). We hypothesized that ethosuximide could block T-type Ca2+ channels, suppress apoptotic factors, and thus prevent hair cell degeneration and preserve auditory function. In the experiment shown in Fig. As mouse hearing can be tested at 3 weeks of age by ABR and we did not observe any loss of hair cells, this was not shown (total mice used = 35). In the experiment shown in Fig. In the experiment shown in Fig. In the experiment shown in Fig. In the experiment shown in Fig. (A) Mean auditory-evoked brainstem response (ABR) thresholds for mice aged between 3 and 14 weeks, exhibiting early hearing loss (at 3 weeks of age) progressing to severe hearing loss by 14 weeks of age. (B) Distortion product oto-acoustic emission (DPOAE) amplitudes decreased in mice aged between 3 and 14 weeks. (A–E and G–I) In 4-week-old mice, auditory-evoked brainstem response (ABR) thresholds in the ethosuximide-treated group (red line) were significantly lower compared to the untreated group (blue line) at a stimulus frequency of 8 kHz (P<0.01). In 6-week-old mice, ABR thresholds in the ethosuximide-treated group (red line) were significantly lower compared to the untreated group (blue line) at a stimulus frequency of 16 kHz (P<0.01). Then, they were trained to press another lever for the minimum number of presses (either 10 or 20) signaled by a discriminative stimulus. During the test trials, the mice encountered conflicting information as they were presented with compound stimuli that combined the auditory and visual cues associated with different numbers of required responses. The mice exhibited behavior that suggested they were using a counting strategy to determine the number of lever presses in these compound test trials. The results of the study showed that the number of lever presses on the compound test trials were around the average of the number of responses in the trials that required 10 and 20 lever presses. Specifically, when the auditory stimulus was associated with a fewer number of required responses, the mice tended to respond with a number of lever presses around the average of the 10 and 20 response trials. According to this, the energy levels of the daughter nucleus can be populated in two ways: The total gamma rays emitted by an energy level (IT) should be equal to \n\nThe effects of acetoxycycloheximide (AXM) and anisomycin (ANI) on approach and escape responses to hypothalamic stimulation in male Swiss mice were studied in an experiment. The mice were placed in a situation where they could start a continuous brain stimulation train by pressing an ON-lever and stop it by pressing an OFF-lever. The results showed that both AXM and ANI significantly decreased the ON-OFF responses, regardless of the level of stimulation provided. These findings suggest that both AXM and ANI have disruptive effects on the reinforcing systems in the brain, which can affect memory and behavioral responses to hypothalamic stimulation in male Swiss mice. both ABR thresholds and middle-ear histology were obtained, the severe nature of signs of OM correlated with the amount of hearing impairment directly. These results claim that unusual auditory sensorimotor gating previously reported in mouse types of 22q11DS could arise from abnormalities in auditory processing. Furthermore, the findings indicate that mice are an excellent model for improved risk of OM in human being 22q11DS patients. mice have proven to be an excellent model for major developmental problems in human being 22q11DS such as cardiovascular abnormalities  and thymic or parathyroid problems , although no gross craniofacial abnormalities such as cleft palate have been reported. Furthermore, both mice and additional mouse models of 22q11DS have been found to show cognitive and behavioural abnormalities associated with human being 22q11DS and schizophrenia, including reduced auditory sensorimotor gating [23-25]. Modern checks of sensorimotor gating depend on the capability to listen to, and previous research have provided some proof for regular hearing in mice and very similar mouse versions [23-25]. To acquire data from a big people of WT and age-matched mice, we centered on 520-26-3 IC50 dimension of click-evoked ABR thresholds, a straightforward and speedy electroencephalographic way of measuring peripheral and early central auditory activity that might be extracted from each hearing for all pets within a litter within a day. We discovered that click-evoked ABR thresholds had been significantly raised in 48% from the pets, in mere one hearing frequently. Anatomical and histological evaluation of the center ear revealed a higher occurrence of OME in mice, which correlated straight with raised ABR thresholds. We conclude that mice, like human being 22q11DS individuals, are susceptible to otitis press and conductive hearing loss. These results suggest that studies of irregular auditory sensorimotor gating in mice need to be revisited using more sensitive assays for hearing loss, and also that mice are a potentially powerful animal model for studying the genetic and environmental causes of otitis press. Both remaining and right ears were tested in 31 of the and 23 of the WT animals, and one ear only in 13 and 20 WT mice. Click ABR thresholds had been higher typically considerably, and more variable also, in both male and feminine mice than within their gender-matched WT littermates (Amount 1A). Median thresholds (and total runs) had been 35 (25-50) and 37.5 (30-55) dB SPL for male and female WT animals, respectively, but 50 (30-75) and 50 (35-85) for male and female mice in the same litters. Median thresholds as a result differed considerably between recordings from and WT mice from the same gender (Wilcoxon Mann-Whitney check, versus WT: p=6×10-6 men, p=9×10-7 females), however, 520-26-3 IC50 not between men and women from the same genotype (Wilcoxon Mann-Whitney check, men versus females: p=0.3 mice. ABR threshold distribution in mice was considerably not the same as the distribution documented from WT mice (Kolmogorov-Smirnov check, p=5×10-8), even though both distributions had been normalised to align the medians (Kolmogorov-Smirnov check on MAPK8 median-normalised data, p=0.02). To be conventional, we described a click ABR deficit to be there when the ABR threshold exceeded 55 dB SPL (criterion threshold indicated by dashed lines in Amount 1A and B), since 55 dB SPL was the best threshold seen in recordings from WT mice. By description, none from the ABR thresholds documented in WT mice exceeded this criterion;.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: A scientist carrying out experiments on hearing aids fits 30 mice that were genetically modified to lose their hearing with the latest technology and were tested to press a lever when they heard a bell. This was set to varying levels of power. At 80% power, 20 mice pressed the lever. At 70% power, 15 mice pressed the lever. At 60% power, 10 mice pressed the lever. Which of the following power levels corresponds to the absolute threshold for hearing the decibels produced by the bell?\nA. 80%\nB. 70%\nC. 60%\nD. Not enough information given.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "D. Not enough information given.",
            "predictions": "D",
            "references": "B"
        },
        "16": {
            "prompt": "<|start_header_id|>system<|end_header_id|>\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nBackground:During transcription, RNA polymerase binds to the DNA strand at a specific region called the promoter. It is worth noting that the transcription process is more complex in eukaryotic cells compared to prokaryotic cells. In eukaryotes, mRNA is formed inside the nucleus and has to pass through nuclear pores to reach the cytoplasm, where ribosomes are located for protein synthesis. The process that occurs within the nucleus to transcribe the genetic code for a protein from DNA to pre-mRNA is known as transcription. Transcription begins with the binding of RNA polymerase to a specific region of the DNA known as the promoter. The RNA molecule that is synthesized is called pre-mRNA, which contains both coding regions called exons and non-coding regions called introns. During the process of transcription, the RNA polymerase adds nucleotides to the growing RNA chain according to the DNA template. However, before the pre-mRNA can leave the nucleus and go on to be translated into a protein, several posttranscriptional modifications need to occur. These modifications include RNA cleavage, excision of introns, rejoining of exons, and the addition of a methylguanosine cap at the 5' end and poly(A) tracks at the 3' end. After these modifications are complete, the resulting mature mRNA molecule leaves the nucleus and migrates into the cytoplasm, where it can be translated into a protein by ribosomes. This process is known as translation. The mature mRNA then travels to the cytoplasm for translation into a protein. During this process, DNA polymerase \"reads\" the existing DNA strands to create two new strands that match the existing ones. These enzymes catalyze the chemical reaction  DNA polymerase adds nucleotides to the three prime (3')-end of a DNA strand, one nucleotide at a time. The process of transcription is a fundamental step in gene expression, where an RNA molecule is synthesized based on the instructions encoded in DNA. This essential process occurs in the nucleus of eukaryotic cells and in the cytoplasm of prokaryotic cells. During transcription, an enzyme called RNA polymerase initiates the process by recognizing a specific section of DNA called the promoter region. As the polymerase moves along the DNA strand, it adds nucleotides to the growing RNA molecule in a process known as elongation. At this point, the RNA molecule is released, and the DNA double helix reforms. The synthesized RNA molecule, known as the primary transcript or pre-mRNA, then undergoes post-transcriptional modifications to become a mature messenger RNA (mRNA). These modifications involve the removal of non-coding regions called introns and the addition of a protective cap and a poly-A tail. Overall, the process of transcription plays a crucial role in translating the genetic information stored in DNA into functional RNA molecules, which are then utilized by the cell for various biological processes.\n\nThere is a multiple-choice question about college medicine. Answer the question by choosing \"A\", \"B\", \"C\" or \"D\". Do not generate any other content.\nQuestion: The transcription of DNA to a molecule of messenger RNA occurs:\nA. on the ribosomes.\nB. in the cytosol.\nC. in the nucleus.\nD. only during cell division.\nAnswer: <|eot_id|><|start_header_id|>assistant<|end_header_id|>\n\n",
            "origin_prediction": "The correct answer is C. in the nucleus.",
            "predictions": "C",
            "references": "C"
        }
    },
    "type": "GEN"
}